1 **Express yourself: Quantitative real-time PCR assays for rapid chromosomal antimicrobial**

2 **resistance detection in *Pseudomonas aeruginosa***

3 Danielle E. Madden[1,2], Olusola Olagoke[1,2], Timothy Baird[2,3], Jane Neill[2,3], Kay A. Ramsay[4], Tamieka A.

4 Fraser[1,2], Scott C. Bell[4,5,6], Derek S. Sarovich[1,2*], and Erin P. Price[1,2*]

5 [1]Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia

6 [2]Sunshine Coast Health Institute, Birtinya, Queensland, Australia

7 [3]Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

8 [4]Child Health Research Centre, The University of Queensland, South Brisbane, Queensland, Australia

9 [5]Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia

10 [6]Translational Research Institute, Woolloongabba, Queensland, Australia

11 Keywords: Antibiotic, AMR, gene expression, *Pseudomonas aeruginosa*, efflux pumps, qPCR, *ampC*,

12 genomics

13 Running title: Assays for rapid AMR detection in *P. aeruginosa*

14 *These authors contributed equally

15 Corresponding authors:

16 Derek Sarovich, dsarovich@usc.edu.au Ph: +61 7 5456 3748

17 Erin Price, eprice@usc.edu.au Ph: +61 7 5456 5568

Abstract

The rise of antimicrobial-resistant (AMR) bacteria is a global health emergency. One critical facet in tackling this epidemic is more rapid AMR diagnosis in serious multi-drug resistant pathogens like *Pseudomonas aeruginosa*. Here, we designed and then validated two multiplex quantitative real-time PCR (qPCR) assays to simultaneously detect differential expression of the resistance-nodulation-division efflux pumps MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM, the AmpC β-lactamase, and the porin OprD, which are commonly associated with chromosomally-encoded AMR. Next, qPCRs were tested on 15 sputa from 11 participants with *P. aeruginosa* respiratory infections to determine AMR profiles *in vivo*. We confirm multiplex qPCR testing feasibility directly on sputa, representing a key advancement in *in vivo* AMR diagnosis. Notably, comparison of sputa with their derived isolates grown in Luria-Bertani broth (±2.5% NaCl) or a 5-antibiotic cocktail showed marked expression differences, illustrating the difficulty in replicating *in vivo* expression profiles *in vitro*. Cystic fibrosis sputa showed significantly reduced *mexE* and *mexY* expression when compared with chronic obstructive pulmonary disease sputa, despite harbouring fluoroquinolone- and aminoglycoside-resistant strains, indicating that these loci are not contributing to AMR *in vivo.* Sputum *ampC* expression was highest in participants receiving carbapenems (6.7-15x), some of whom were simultaneously receiving cephalosporins, the latter of which would be rendered ineffective by the upregulated *ampC*. Our qPCR assays provide valuable insights into the *P. aeruginosa* resistome, and their use on clinical specimens will permit timely treatment alterations that will improve patient outcomes and antimicrobial stewardship measures.

38 **Introduction**

39 The persistent rise in the prevalence and dissemination of antimicrobial-resistant (AMR) bacteria
40 threatens to push humankind towards a post-antibiotic world (1) where untreatable superbugs
41 endanger global health and food security and cause significant morbidity, mortality and economic
42 burden (2). The opportunistic Gram-negative bacterium, *Pseudomonas aeruginosa*, is a member of
43 the 'ESKAPE' group of AMR pathogens that represent the greatest concern to global health (3). *P.*
44 *aeruginosa* can cause life-threatening infections (4), including in those with chronic respiratory
45 diseases where localised immune defences are compromised such as cystic fibrosis (CF) or chronic
46 obstructive pulmonary disease (COPD) (5). Once infection is established, *P. aeruginosa* eradication is
47 made more difficult by many factors, including its high intrinsic AMR and its capacity to develop
48 multi-drug resistance (MDR) to all classes of clinically-relevant antibiotics (6).

49 AMR diagnostics are a critical weapon in our battle against superbugs as they enable rapid, cost-
50 effective, and high-throughput AMR detection, leading to more judicious and targeted antibiotic use
51 (7). However, a lack of such diagnostics means that broad-spectrum antimicrobials are commonly
52 used in the clinic in lieu of personalised treatments guided by antimicrobial sensitivity, genotype,
53 and gene expression data (8). This practice, exacerbated during the COVID-19 pandemic (9), has
54 unfortunately contributed to the emergence, persistence, and spread of AMR and MDR pathogens
55 worldwide, with potentially devastating outcomes including treatment failure and mortality (10).
56 Advancements in next-generation sequencing (NGS) technologies are enabling close-to-real-time
57 identification of AMR (11). However, it is currently impractical and costly to use these technologies
58 for rapid, high-throughput detection (12); as such, their implementation in routine clinical
59 diagnostics is not yet feasible. Instead, nucleic acid-based detection platforms such as real-time PCR
60 remain vital – and substantially cheaper, simpler, and more accessible in routine clinical
61 microbiology services than NGS – for the rapid identification of pathogens and their AMR
62 determinants (12). In addition to identifying AMR-conferring single-nucleotide polymorphisms

63 [SNPs] (13, 14), insertions/deletions (15), copy-number variants (16), gene gain (17, 18), or gene loss
64 (19), targeting altered RNA expression of key AMR loci (20-23) provides a rapid way to identify the
65 phenotypic consequences of the myriad genotypic variants that underpin AMR. For example, a
66 quantitative real-time PCR (qPCR) targeting upregulation of three key AMR resistance-nodulation-
67 division (RND) efflux pumps in the melioidosis pathogen, *Burkholderia pseudomallei*, enables the
68 simultaneous identification of meropenem (MEM) resistance, and decreased susceptibility towards
69 doxycycline and co-trimoxazole, in a single reaction (24).

70 Due to the large number of genetic mutations that can confer AMR in *P. aeruginosa* (25, 26), it
71 remains impractical to target each individual variant using PCR. Fortunately, most clinically-relevant
72 AMR in *P. aeruginosa* is thought to be conferred by a handful of key mechanisms, some of which
73 alter gene expression to drive the AMR phenotype (25). The primary AMR-conferring mutations in *P.*
74 *aeruginosa* include those that cause: i) *oprD* inactivation or repression, which commonly leads to
75 carbapenem resistance (27, 28); ii) *ampC* hyper-production, a predominant cause of β-lactam AMR
76 (25); iii) DNA gyrase A (*gyrA*) alteration, associated with fluoroquinolone (FQ) AMR (13, 29); and iv)
77 upregulation of one or more RND efflux pumps, leading to AMR or MDR (23). The most important
78 AMR-conferring RND efflux pumps in *P. aeruginosa* are MexAB-OprM (30) (FQs, β-lactams including
79 carbapenems (31), and β-lactam inhibitors (25)), MexEF-OprN (FQs) (32), MexXY (33)
80 (aminoglycosides and FQs (34)), and MexCD-OprJ (35) (FQs (36) and some fourth-generation
81 cephalosporins (37)).

82 Whilst PCR assays exist to individually detect differential gene expression of *ampC* (20, 26, 34), *mexB*
83 (22, 38), *mexX* (20, 39), *mexY*, *mexD, mexF* (22, 23), *mexA* and *oprD* (22, 34, 39) in *P. aeruginosa*,
84 none simultaneously detect expression of these genes. In addition, nearly all *P. aeruginosa* AMR
85 gene expression studies to date have assessed lab-cultured isolates (23, 38); with only one published
86 study assessing AMR gene expression *in vivo*, whereby singleplex assays were used to detect *ampC*

87 and *mexX* expression in 31 CF sputa, followed by comparison with corresponding derived isolates
88 (20).

89 To address these knowledge gaps, we developed and validated two multiplex qPCR assays to
90 simultaneously detect altered expression of six key genes that confer AMR towards most clinically-
91 relevant antibiotic classes, using *rpsL* as an internal reference gene for expression normalisation.
92 qPCRs were initially tested in cultures, and subsequently directly on 15 sputa, to permit *in vivo P.*
93 *aeruginosa* gene expression characterisation (20), thus removing transcriptional biases introduced
94 by culturing. qPCR results were also correlated with current anti-pseudomonal treatment to
95 determine the impact of antibiotic therapy on *in vivo* AMR gene expression, along with strain
96 phenotype and predicted *in silico* AMR genotype data.

97 ## Methods

98 **Ethics statement and participant recruitment.** This study was approved by The Prince Charles
99 Hospital (TPCH) Human Research Ethics Committee, project IDs HREC/13/QPCH/127 (CF) and
100 HREC/2019/QPCH/48013 (COPD). Site-specific approvals were obtained for CF recruitment at TPCH,
101 Brisbane, Australia, and COPD recruitment at Sunshine Coast Hospital and Health Service, Sunshine
102 Coast, Australia. CF sputa were collected from participants with chronic *P. aeruginosa* infection who
103 were admitted to the Cystic Fibrosis Centre at TPCH for intravenous antibiotic therapy; COPD sputa
104 was collected from participants either admitted to Sunshine Coast University Hospital (SCUH) for
105 pulmonary exacerbations, or whose symptoms were being managed at home as part of the
106 Respiratory Acute Discharge Service program; whether they had acute or chronic *P. aeruginosa*
107 infection was not known. All participants provided written consent.

108 **Total RNA extraction and microbial RNA enrichment from sputa.** Nine sputa from five CF
109 participants, and six sputa from six COPD participants (40) (Table 1), all with high-load *P. aeruginosa*
110 infections according to sputum culture onto MacConkey agar (Oxoid, Heidelberg West, VIC,
111 Australia), were subjected to total RNA extraction to determine *in vivo P. aeruginosa* AMR gene
112 expression profiles. Sputa were collected directly into RNA stabilisation reagent (10mM EDTA, 25mM
113 sodium citrate, 700g/L ammonium sulphate; pH=5.2; Sigma-Aldrich, Castle Hill, NSW, Australia) to
114 immediately halt transcriptional activity, and kept at 4◦C until RNA extraction (up to ~1 month).
115 Between 30 µL and 1 mL sputum was placed into 0.5-6 mL TRI Reagent LS (Sigma) and 30-240 µL 2-
116 mercaptoethanol (Sigma) aliquoted into sterile, RNase-free 2 mL O-ring tubes (SSIBio, Lodi, CA, USA)
117 containing ~100 µL equal mixture of 0.1 and 0.5 mm zirconia beads (Daintree Scientific, St Helens,
118 Tasmania, Australia). Tubes were parafilmed and subjected to four rounds of bead beating at 30 sec
119 pulses using the Minilys tissue homogeniser on the medium setting (Bertin Instruments, Montigny-
120 le-Bretonneux, France), with samples cooled on ice for >30 sec after each round to minimise RNA
121 degradation. Extracted RNA was treated with DNase Max (Qiagen), confirmed DNA-free using a 16S

122 ribosomal RNA gene PCR (41), and host RNA-depleted using MICROBEnrich (Thermo Fisher Scientific,
123 Seventeen Mile Rocks, QLD, Australia) as per manufacturer's instructions. cDNA (iScript; Bio-Rad,
124 Gladesville, NSW, Australia) was qPCR-tested at neat and 1:10 concentrations.

125 **Growth conditions and antibiotic sensitivity testing.** Nineteen *P. aeruginosa* strains (12 CF, 7 COPD)
126 were isolated from sputa using MacConkey agar and incubated at 37◦C for 24 h. Subcultures were
127 grown on Luria-Bertani (LB) agar (Oxoid) under the same conditions. All strains were confirmed as *P.*
128 *aeruginosa* by rapid chelex-100 (Bio-Rad) heat soak extraction (42) followed by *ecfX* real-time PCR
129 on a 1:50 dilution of the chelex supernatant (43). Susceptibility towards amikacin (AMK; 30µg),
130 cefepime (30µg), ceftazidime (CAZ; 30µg), ciprofloxacin (5µg), colistin (10µg), imipenem (10µg),
131 piperacillin (30µg), piperacillin-tazobactam (100µg/10µg), polymyxin B (300U), and tobramycin (TOB;
132 10µg) were determined by disc diffusion (Edwards Group, Murrarie, QLD, Australia); Etests were
133 used for MEM susceptibility testing (bioMérieux, Baulkham Hills, NSW, Australia). Sensitivity,
134 intermediate resistance, and AMR were determined using CLSI M100S-Ed27:2021 guidelines (Table
135 1). PAO1 (LMG 12228) was included as a wild-type reference. MDR was defined as non-susceptibility
136 to at least one antibiotic in three or more antibiotic classes (44).

137 **Growth experiments and RNA extraction.** To assess AMR gene expression levels in derived cultures,
138 a starting inoculum of 10^5 cells was grown to late-log phase (OD_{600}≈1) with orbital shaking at 250 rpm
139 (Ratek Laboratory Equipment [model number OM11], Boronia, VIC, Australia) for 16 h at 37◦C in 2mL
140 LB broth ±2.5% NaCl. RNA was extracted using TRI Reagent (Sigma-Aldrich) and treated with TURBO
141 DNase (Thermo Fisher Scientific) according to manufacturer's instructions. 1:10-diluted DNA-free
142 RNA was converted to cDNA using iScript. cDNA was diluted 1:25 in molecular-grade H_2O prior to
143 qPCR.

144 We also attempted to induce AMR gene expression in two *P. aeruginosa* cultures, SCHI0002.S.9 and
145 SCHI0010.S.1, using sub-inhibitory concentrations (0.25µg/mL each) of five antibiotics not used in *P.*
146 *aeruginosa* treatment but known to induce its RND efflux pumps – gentamicin for *mexX* upregulation

147 (45), novobiocin for *mexB* upregulation (31), norfloxacin for *mexC* upregulation (46),
148 chloramphenicol for *mexE* upregulation (47) and ampicillin for *ampC* upregulation (48). These strains
149 were selected as both encode MDR phenotypes; in addition, SCHI0010.S.1 encodes a high-
150 consequence frameshift mutation in MutS (R360fs), resulting in a hypermutator phenotype (49).

151 **Multiplex AMR locus qPCR assay design and PCR conditions.** To quantify *mexAB-oprM*, *mexCD-oprJ*,
152 *mexEF-OprN*, *mexXY-OprM*, *ampC*, and *oprD* expression, two multiplex assays targeting the *mexB,*
153 *mexC, mexE*, *mexY, ampC*, and *oprD* genes, respectively, were designed (Table 2). A BLAST database
154 comprising 730 *P. aeruginosa* genomes (50-54) was used to identify conserved regions for oligo
155 design. Oligo self-dimers and heterodimers were assessed and avoided as previously described (55).
156 Each PCR consisted of 1× SsoAdvanced Universal Probes Supermix (Bio-Rad), optimised primer and
157 probe concentrations (Macrogen Inc., Geumcheon-gu, Seoul, South Korea; Table 2), 1 µL genomic
158 DNA (gDNA) or cDNA template, and PCR-grade H_2O, to 5 µL. Isolate gDNA/cDNA thermocycling
159 comprised enzyme activation at 95◦C for 2 min, followed by a 2-step program (95◦C for 5 sec and
160 60◦C for 15 sec) for 45 cycles; for sputum cDNA, a 3-step program (95◦C for 5 sec, 60◦C for 15 sec,
161 and 72◦C for 15 sec) for 45 cycles was used to enhance *P. aeruginosa* detection from polymicrobial
162 DNA.

163 **qPCR assay limits of detection (LoD) and quantification (LoQ).** LoD and LoQ values were determined
164 for each assay when in multiplex format using 1:10 serial dilutions of SCHI0005.S.10 *P. aeruginosa*
165 genomic DNA ranging from 40 to 4×10^{-6}ng across eight replicates, as previously described (56, 57).
166 Genome equivalents (GEs) were calculated based on the average PAO1 genome size of 6.22Mbp and
167 a single copy of each gene. For all assays, all samples were run in duplicate, and at least two no-
168 template controls were included in each run.

169 **qPCR normalisation and analysis.** The constitutively expressed *rpsL* gene was used to normalise
170 AMR gene expression via the difference in cycles-to-threshold (ΔC_T) method (34, 58). After *rpsL*
171 normalisation, ΔC_T values were further normalised against either PAO1 expression, or to

172 SCHI0070_D2 COPD sputum ($\Delta\Delta C_T$), the latter of which enabled gene expression comparison among
173 sputa, and between sputa and derived isolates. SCHI0070_D2 COPD sputum was chosen for
174 normalisation as this participant had no recent history of anti-pseudomonal antibiotic treatment, its
175 derived isolate, SCHI0070.S.1, was sensitive towards all 11 anti-pseudomonal antibiotics (Table 1),
176 and there was good gene expression across all seven loci for this sample. For AMR loci lacking
177 detectable PCR amplification, a C_T value of 45 was assigned to permit visualisation of genes with very
178 low/no expression. According to previously defined criteria (23), strains were regarded as hyper-
179 producers if their AMR loci exhibited >10-fold higher expression compared with PAO1, except for
180 *mexB* and *mexY,* which were considered hyper-producing if >3-fold higher expression than PAO1 (23,
181 34, 38).

182 **AMR prediction from genomes.** *In silico* AMR prediction for 16 genome-sequenced isolates, plus
183 PAO1 (Table 1), was carried out using the *P. aeruginosa*-specific database in ARDaP v1.9 (59)
184 (available at: https://github.com/dsarov/ARDaP). The genomes of 14 strains have been previously
185 published (13); paired-end Illumina genomes for SCHI0065.S.1 and SCHI0070.S.1 were generated in
186 the current study and appended to NCBI BioProject PRJNA761496. We did not sequence
187 SCHI0018.S.11, SCHI0038.S.2, or SCHI0038.S.4 as these data were not considered essential for study
188 outcomes.

189 **Statistical analysis.** Gene expression differences were assessed using a two-way analysis of variance
190 test and Tukey's multiple comparison test using GraphPad Prism (GraphPad Software Inc., CA, USA).
191 Corrected *p* values of <0.05 were considered significant.

192 **Results**

193 **Multiplex qPCR assay performance.** To assess assay sensitivity, LoD and LoQ values were
194 determined using a 10-fold DNA dilution series (40 ng to 0.04 fg). The LoD for all assays was 400 fg
195 (59 GEs), the LoQ for *mexB, mexE* and *mexC* was 400fg (59 GEs), and the LoQ for *rpsL, ampC, mexY*
196 and *oprD* was 4000 fg (587 GEs) (Figures S1 and S2).

197 **Antibiotic susceptibility profiles.** Testing towards 11 anti-pseudomonal antibiotics identified much
198 higher rates of AMR (range: 0-9 antibiotics) and MDR (10/12 strains) in CF-derived isolates when
199 compared with COPD-derived isolates (range: 0-2 antibiotics; 0/7 MDR strains) (Table 1). This was
200 consistent with much greater antibiotic use in the CF cohort (Table 1) (40). The lowest susceptibility
201 rates were towards cefepime (0% CF and 100% COPD) and piperacillin (33% CF and 100% COPD),
202 whereas all 19 strains were susceptible to colistin and polymyxin B (Table 1). Interestingly, cefepime
203 is rarely used for CF treatment at TPCH, indicating probable cross-resistance towards this antibiotic
204 in all CF-derived isolates. None of the participants were receiving polymyxins; as such, no AMR was
205 expected towards these antibiotics.

206 ***In silico* AMR prediction.** Genomic analysis of the derived *P. aeruginosa* isolates revealed a much
207 greater number of AMR determinants in the CF-derived strains (Table 1). Although some AMR
208 determinants were identified in COPD isolates, none were associated with dysregulated expression
209 of the six AMR loci. In contrast, many CF-derived isolates encoded mutations predicted to alter gene
210 expression of our qPCR gene targets (Table 1). Specifically, *ampC* overexpression was predicted in
211 SCHI0030.S.2 and SCHI0030.S.3 due to AmpD regulator loss (P42fs) (60); *mexAB-oprM*
212 overexpression was predicted in SCHI0002.S.9 and SCHI0002.S.12 due to a D187H missense
213 mutation in the NalD regulator (61); and *mexCD-oprJ* overexpression was predicted in SCHI0030.S.4
214 due to NfxB regulator loss (F126fs) (62). No mutations associated with *mexEF-oprN* or *mexXY-oprM*
215 overexpression were identified. Although not associated with gene expression changes, *oprD* loss

216 was predicted in SCHI0002.S.8 (W339Ter) and SCHI0030.S.3 (G193fs), which is linked to carbapenem
217 resistance, especially when associated with *ampC* upregulation (25, 63) as observed in SCHI0030.S.3.

218 Other AMR determinants were identified in our strain dataset, including multiple determinants
219 encoding decreased susceptibility or AMR towards CIP (GyrA T83I, D87H or D87N, GyrB S466F and
220 ParE A473V (64)) (Table 1). In addition, an R504C missense variant in FtsI, known to confer resistance
221 to β-lactams (65), was detected in three CF-derived, multi-β-lactam-resistant isolates (SCHI0002.S.8,
222 SCHI0030.S.2, and SCHI0030.S.3), and a FusA1 missense mutation, A555E (66), was identified in CF-
223 derived isolate SCHI0010.S.1 (AMK- and TOB-resistant) (Table 1). Finally, MexEF-OprN loss was
224 predicted in SCHI0013.S.2 and SCHI0013.S.12 due to a frameshift (R229fs) in the MexE membrane
225 fusion protein, and in SCHI0030.S.2 and SCHI0030.S.3 due to the introduction of a stop codon
226 (Y37Ter) in the MexF multidrug inner membrane transporter (67). Unlike the AMR variants, these
227 *mexE* and *mexF* mutations render the MexEF-OprN pump inoperable, and thus unable to contribute
228 towards AMR, irrespective of *mexEF-oprN* upregulation.

229 **Comparison of AMR variant prediction with *in vitro* AMR gene expression.** Relative AMR gene
230 expression in derived *P. isolates* grown in LB broth (*n*=15; Figure S3), LB+NaCl (*n*=14; Figure S4), or a
231 5-antibiotic cocktail (*n*=2; Figure S5) was assessed. All qPCR targets exhibited expression in at least
232 one strain; however, in some strains, particularly the CF-derived isolates, certain genes exhibited no
233 expression (Figures S3-S5). Just two loci were expressed in all tested strains across all conditions: the
234 housekeeping gene *rpsL* (C_T=25.3±1.97) and *mexB* (C_T=29.0±2.14). *oprD* was expressed in all strains
235 except SCHI0039.S.1 grown in LB+NaCl. In contrast, *ampC*, and *mexC*, *mexE*, and *mexY* were
236 expressed in 1, 23, 26, and 2 of the 31 tested strains, respectively. Genetic analysis of all qPCR-
237 targeted loci confirmed 100% primer and probe matches in those strains with genomic data, thereby
238 ruling out assay failure as a cause of undetectable expression.

239 Unexpectedly, there was no concordance between *in silico* AMR predictions and qPCR results for
240 strains grown under any of the tested conditions. SCHI0030.S.2 and SCHI0030.S.3, which were

241 predicted to upregulate *ampC* through a previously undocumented AmpD frameshift variant (P42fs),
242 exhibited negligible or no *ampC* expression when grown in LB broth or LB+NaCl (Figures S3 and S4).
243 In contrast, SCHI0010.S.1, which does not encode any known chromosomal variant associated with
244 *ampC* upregulation (Table 1), demonstrated *ampC* hyper-expression (43x) in LB broth relative to
245 PAO1, although no detectable *ampC* expression under salt (Figure S2) or antibiotic stress (Figure S3).
246 Similarly, SCHI0002.S.9 and SCHI0002.S.12 failed to overexpress *mexB*, and SCHI0030.S.4 failed to
247 overexpress *mexC*, despite predicted upregulation. Once again, SCHI0010.S.1 grown in LB, but not in
248 LB+NaCl, unexpectedly hyper-expressed *mexB* (19x), *mexC* (19x), *mexE* (24x), and *mexY* (16x) in lieu
249 of encoding any known variants associated with upregulation of these loci. No other strain tested
250 under any condition upregulated *mexB*, *mexC*, *mexE*, or *mexY*. Although no strains were predicted to
251 exhibit *oprD* downregulation, *oprD* was not expressed in SCHI0039.S.1 grown in LB±NaCl, and was
252 significantly downregulated in SCHI0010.S.1 grown in LB+NaCl (Figures S3 and S4). All other strains
253 exhibited good *oprD* expression, including SCHI0002.S.8 and SCHI0030.S.3; although these strains
254 encode truncated OprD, these deleterious mutations occur downstream of the oligo-binding sites,
255 and are therefore undetected by our assay.

256 **AMR gene expression in sputa.** All COPD sputa yielded more similar expression profiles to the
257 SCHI0070_D2 COPD control than any of the nine CF sputa (Figure 1). The only overexpressed loci in
258 the CF or COPD sputa were: *ampC* (4/9 CF [1.7-15.1x] and 2/5 COPD [1.7-3.5x]), *mexB* (3/5 COPD
259 [1.5-2.5x]), *mexC* (2/9 CF [1.7-2.1x] and 2/5 COPD [6.4x each]), *mexY* (4/5 COPD [1.8-7.3x]), and *oprD*
260 (3/5 COPD [1.7-51x]) (Figure 2). All CF sputa exhibited downregulation or no expression of *mexB*
261 (≥4.0x), *mexE* (≥3.9x), *mexY* (≥5.2x), and *oprD* (≥377x), and 6/9 were downregulated or had no
262 detectable expression for *mexC* (≥3.4x). When comparing CF and COPD sputum expression, no
263 significant difference was observed for *ampC*, *mexB*, *mexC*, or *oprD*; in contrast, *mexE* and *mexY*
264 were all significantly downregulated in CF sputa (Figure 1).

265 Correlation of qPCR results with antibiotic treatment (Table 1) identified that sputum *ampC*
266 expression levels were a good indicator of current β-lactam use, with 4/5 sputa with elevated *ampC*
267 expression collected from participants contemporaneously receiving β-lactams (SCHI0002_D8,
268 SCHI0010_D7, SCHI0013_D4, and SCHI0018_D8). Notably, 2/3 sputa (SCHI0002_D8 and
269 SCHI0013_D4) obtained from participants being treated with MEM, either with or without CAZ,
270 overexpressed *ampC* at high levels (6.7-15x); in contrast, *ampC* expression was only moderately
271 upregulated (1.7-1.9x) in two sputa (SCHI0010_D7 and SCHI0018_D8) from participants on CAZ but
272 not MEM (Table 1; Figure 2). *ampC* was downregulated or not expressed in eight sputa (Figure 2) - of
273 these, four were collected from participants receiving no antibiotics at the time of collection, three
274 were receiving antibiotics other than β-lactams, and just one (SCHI0002_D329) was receiving CAZ
275 and MEM at the time of sputum collection (Table 1).

276 **AMR gene expression between sputa and *in vitro* cultures.** Sputum AMR gene expression was
277 compared with derived cultures grown in LB broth (Figure S3), LB+NaCl (Figure S4), and a 5-antibiotic
278 cocktail (Figure S5) to determine whether culture AMR gene expression was reflective of *in vivo*
279 conditions. Overall, there was very poor concordance between *in vivo* and *in vitro* expression
280 profiles across all tested *in vitro* conditions, with most loci exhibiting dissimilar expression between
281 derived isolates and their corresponding sputa. Most striking was *oprD*, which, in most cases, was
282 upregulated in strains grown under the three *in vitro* conditions (Figures S3-S5) yet largely
283 downregulated *in vivo* (Figure 2).

284 **RND efflux pump expression during antibiotic treatment.** The four longitudinal sputa collected from
285 SCHI0030, who received intravenous TOB and aztreonam for 15 days, provides an interesting case
286 study for observing AMR gene expression dynamics before, during, and after antibiotic treatment
287 (Table 1). Although TOB has previously been shown to induce MexXY-OprM expression in CF sputa
288 (20), we unexpectedly did not observe AMR gene expression changes in SCHI0030 sputa (Figure 2).
289 Five sputa from other CF participants also showed limited or no *mexY* expression. In comparison,

290 *mexY* was significantly upregulated in 4/5 COPD sputa (Figure 2), none of whom have ever received

291 TOB (Table 1).

292 **Discussion**

293 Here, we developed and validated two multiplex qPCR assays for the simultaneous detection of
294 altered AMR locus expression in the ESKAPE pathogen, *P. aeruginosa*. When run in multiplex format,
295 our qPCRs showed very good to excellent LoD and LoQ values. qPCRs can be used both on *P.*
296 *aeruginosa* cultures and directly on human RNA-depleted sputa, the latter of which provides *in vivo*
297 expression profiling that overcomes transcriptional bias introduced with *in vitro* culture (20).
298 Building upon the pioneering work of Martin and colleagues, who first reported limited correlation
299 in *ampC* and *mexX* expression between sputa and corresponding derived isolates (20), we also
300 observed poor concordance between *in vivo* and *in vitro* expression profiles across six tested AMR
301 loci. Further, we found surprisingly poor correlation between *in silico*-predicted and *in vitro* AMR
302 gene expression. These findings raise questions about the clinical utility of *in vitro* antimicrobial gene
303 expression profiling and highlight the need for more work in this critical area of AMR research.

304 **AmpC-driven AMR.** We found that sputum *ampC* expression correlated well with contemporaneous
305 β-lactam treatment. In particular, two CF participants (SCHI0010 and SCHI0018) receiving CAZ but no
306 other β-lactams overexpressed *ampC* at moderate levels (1.7-2x); this overexpression increased to
307 6.7-15x in two other participants (SCHI0002 and SCHI0013) receiving MEM (Table 1; Figure 2).
308 Carbapenems such as MEM can be potent *ampC* inducers (63) and can remain effective even when
309 *ampC* expression is elevated (25), whereas cephalosporins such as CAZ are relatively weak inducers
310 of *ampC* and are readily hydrolysed by this enzyme (25). Our findings confirm that MEM can act as a
311 strong inducer of *ampC* expression *in vivo*. In light of this, we recommend that *P. aeruginosa*
312 infections should not simultaneously be treated with carbapenems and cephalosporins due to
313 potential *ampC* induction, which would render cephalosporin (and likely other β-lactam) antibiotics
314 ineffective (25). In contrast, eight sputa exhibited downregulated or no *ampC* expression (Figure 2),
315 seven of which were taken from participants either not on antibiotics or not receiving β-lactams at
316 the time of sample collection, which likely explains the lack of β-lactam-driven *ampC* selection

317 pressure. Of note, two COPD sputa, SCHI0109 and SCHI0050_D3, showed *ampC* upregulation (1.7-
318 3.5x), despite neither participant receiving contemporaneous β-lactam therapy. Whilst the basis for
319 this upregulation is unknown, we speculate that β-lactam use in these participants would be
320 ineffective for *P. aeruginosa* eradication. Taken together, our results demonstrate that routine *ampC*
321 qPCR testing of *P. aeruginosa*-positive specimens is a useful diagnostic for monitoring *in vivo*
322 cephalosporin efficacy, enabling more rapid treatment shifts in instances where *ampC* is
323 upregulated.

324 Unlike sputa, almost all derived isolates failed to express *ampC* when grown in three different liquid
325 media. The exception was the derived isolate from CF participant SCHI0010. In LB broth,
326 SCHI0010.S.1 exhibited *ampC* hyper-expression (15x relative to SCHI0070_D2, and 43x relative to
327 PAO1; Figure S3), yet the corresponding sputum showed only modest *ampC* upregulation (1.7x;
328 Figure 2). This finding was unexpected as SCHI0010.S.1 does not encode any known chromosomal
329 variant associated with *ampC* upregulation (Table 1), and did not overexpress *ampC* when grown in
330 LB+NaCl or the 5-antibiotic cocktail (Figures S4-S5). These results indicate that SCHI0010.S.1 encodes
331 an enigmatic determinant for upregulating *ampC* expression when grown under particular
332 conditions. Whilst the basis of this overexpression requires further investigation, we postulate that it
333 may be driven by global transcriptional regulator inactivation due to its hypermutator status,
334 resulting in marked transcriptome differences affecting multiple gene pathways. In contrast, strains
335 SCHI0030.S.2 and SCHI0030.S.3, both predicted to upregulate *ampC* due to a truncated AmpD,
336 exhibited negligible or no *ampC* expression *in vitro* (Figures S3-S4). This result correlated with all
337 longitudinal SCHI0030 sputa which exhibited significantly downregulated *ampC* expression. One
338 possibility for the lack of *ampC* expression in SCHI0030 is that the AmpD P42fs mutation may only
339 confer a partially de-repressed *ampC* phenotype (26); another possibility is that additional
340 chromosomal determinants, such as those occurring in other AmpD homologues (26) or DacB (68),
341 may be required to confer *ampC* upregulation (60) in AmpD P42fs-encoding strains.

342 Expression of *ampC* was also undetectable in the MDR strain, SCHI0002.S.9, across the three *in vitro*
343 conditions (Figures S3-S4). Whilst this observation is consistent with the lack of predicted *ampC*
344 dysregulation in the SCHI0002.S.9 genome, it does not reflect the AMR phenotype of this strain,
345 which was resistant to all six tested penicillin, cephalosporin, and carbapenem antibiotics (Table 1).
346 In addition, the corresponding SCHI0002_D8 sputum displayed the greatest *ampC* upregulation (15x;
347 Figure 2), probably due to contemporaneous CAZ and MEM treatment (Table 1). One possible
348 explanation for these spurious results is that high sputum *ampC* levels are conferred by an un-
349 retrieved *P. aeruginosa* strain (20), as supported by two distinct AMR phenotypes and genotypes
350 isolated from SCHI0002_D8, SCHI0013_D4, and SCHI0030_D50 sputa (Table 1). Indeed, phenotypic
351 and genotypic diversity of *P. aeruginosa* is well-documented in chronic CF infections (69), and
352 increasingly in COPD infections (70). Another explanation is that *ampC* expression in SCHI0002
353 strains may require MEM (20) or cefoxitin (71) rather than ampicillin (48) for *in vitro* induction, as
354 certain antibiotics are known to be better than others for inducing *ampC* (20). However, antibiotic
355 induction only provides a crude representation of *in vivo P. aeruginosa* activity, as the lung
356 environment is exceptionally difficult to mimic *in vitro* (20, 69, 72). The lack of correlation between
357 *ampC* upregulation in sputa and derived cultures (Figures S3-S5) has also been reported in a
358 separate study (20), and emphasises the challenges in replicating *in vivo* conditions *in vitro*.

359 **Efflux-mediated AMR.** *mexB*, *mexC*, *mexE* and *mexY* represent the RND efflux pumps most
360 frequently associated with AMR and MDR in *P. aeruginosa* (23, 25). As most CF participants were
361 being treated with anti-pseudomonal antibiotics at the time of sputum collection, and many of their
362 derived isolates encode key mutations associated with altered RND efflux pump expression (Table
363 1), we expected upregulation of these four efflux pumps in CF sputa. It was therefore surprising that
364 *mexC* was the only efflux system that demonstrated modest (1.7-2.1x) upregulation in a few patients
365 (2/9 CF sputa), whereas the other RND efflux systems were largely downregulated, or switched off
366 entirely, in CF sputa (Figure 2). Also surprising was that most COPD sputa showed good expression of
367 these loci, despite only two COPD participants contemporaneously receiving anti-pseudomonal

368 antibiotics, and almost no AMR phenotypes or efflux pump expression-altering genotypes in the
369 derived COPD isolates (Table 1). This difference between diseases was most apparent for *mexE* and
370 *mexY*, which were significantly downregulated in CF but not COPD sputa (Figure 1). Although our
371 dataset is small, these observations suggest that RND efflux pump expression, and particularly *mexE*
372 and *mexY* expression, may not be required for chronic *P. aeruginosa* persistence in CF airways. This
373 finding contradicts prior *in vitro* work suggesting that MexXY-OprM efflux pump upregulation is
374 necessary for *P. aeruginosa* survival in the CF lung (73). We further postulate that the MexEF-OprN
375 and MexXY-OprM RND efflux pumps may have a minimal role, if any, in conferring AMR in *P.*
376 *aeruginosa in vivo*. *mexE* and *mexY* qPCR testing across a larger CF and COPD sputum panel is
377 needed to determine to veracity of our findings.

378 One possible explanation for efflux pump downregulation in CF sputa is that the CF cohort all
379 harboured chronic *P. aeruginosa* infections, whereas the COPD cohort potentially only had transient
380 (i.e. acute) infections. Like virulence factors (74), RND efflux pump expression may be upregulated
381 during the acute phase but then downregulated once *P. aeruginosa* transitions to a chronic lifestyle,
382 the latter of which is characterised by biofilm formation and reduced metabolic activity (25, 75). In
383 support of this hypothesis, longitudinal sputa collected from CF participant SCHI0030 just prior,
384 during, and after a 15-day course of intravenous TOB and aztreonam treatment showed virtually no
385 change in RND efflux pump expression, with all AMR genes (including *mexY*) downregulated (Figure
386 2) despite the aminoglycoside onslaught. In addition, one of two SCHI0030 strains obtained 35 days
387 after antibiotic cessation was fully susceptible to all 11 tested antibiotics, including TOB, hinting at
388 insufficient antibiotic penetration due to biofilm. As ours is one of the few studies to investigate *P.*
389 *aeruginosa* AMR gene expression *in vivo*, and the first to assess COPD sputa, more work is required
390 to verify these hypotheses, as there remains stark limitations in our understanding of the
391 characteristics of *P. aeruginosa* infection (including AMR development), particularly in people with
392 COPD (76). Examining *in vivo* AMR gene expression dynamics over a long-term *P. aeruginosa*
393 infection would shed important information about the adaptive processes that occur during the

394 transition from acute infection to chronic persistence. We anticipate that our multiplex assays will
395 be a valuable tool for such studies.

396 Analysis of RND efflux expression among the CF-derived isolates encoding predicted RND efflux
397 upregulation revealed that almost none demonstrated increased efflux pump expression *in vitro*
398 (Figures S3-S5). Curiously, the MDR and hypermutated isolate SCHI0010.S.1, which does not encode
399 any known mutations associated with RND efflux pump upregulation, exhibited *mexB* (5.3x), *mexC*
400 (1.7x), *mexE* (1.5x), and *mexY* (28x) overexpression when grown in LB, although not when grown in
401 LB+NaCl or the 5-antibiotic cocktail (Figures S3-S5). These results indicate that there are growth-
402 specific requirements associated with upregulation of these genes. Furthermore, these observations
403 collectively indicate that *in vitro* efflux pump expression is not a good proxy for AMR phenotype, as
404 our CF-derived *P*. *aeruginosa* isolates demonstrate extensive MDR, yet we were unable to reproduce
405 their expected gene expression alterations *in vitro*. Our results contradict other *in vitro* experiments
406 reporting RND efflux pump hyper-expression as a major contributing factor to AMR development in
407 CF airway-derived *P. aeruginosa* (34, 39). Caution should thus be taken when attempting to correlate
408 predicted AMR phenotypes with *in vitro* RND efflux pump expression profiles due to considerable
409 AMR gene expression changes exhibited under different culture conditions.

410 **OprD-mediated AMR.** As with the other AMR loci, we saw an unexpectedly poor correlation
411 between *in vitro* and *in vivo oprD* expression. Whereas 17/19 *in vitro* cultures expressed *oprD* at high
412 levels (Figures S3-S5), 9/9 CF and 2/5 COPD sputa exhibited no detectable *oprD* expression (Figure
413 2). This finding strongly suggests that *oprD* downregulation is a common, and potentially dominant,
414 adaptive *in vivo* trait in chronic *P. aeruginosa* infections. Another noteworthy observation is that *in*
415 *vivo oprD* downregulation was not strictly associated with contemporaneous carbapenem use, as
416 only three of the CF sputa were obtained during carbapenem treatment, and none of the COPD
417 participants had ever received carbapenems. We posit that this adaptive mechanism may provide a
418 rapid, efficient, and effective way for *P. aeruginosa* to evade carbapenems in lieu of encoding

419 functional *oprD* loss. In support of this hypothesis, two prior studies reported decreased *oprD*
420 expression as a cause of carbapenem AMR in 19/33 (58%) (77) and 39/117 (33%) (78) clinical
421 isolates. However, another study showed that *in vitro oprD* downregulation in carbapenem-resistant
422 isolates is a rare event, occurring in just 5/40 (13%) isolates (34). As our study illustrates, the
423 markedly different *oprD* expression profiles observed among studies may reflect differing *in vitro*
424 growth conditions; nevertheless, these *in vitro* findings show that *P. aeruginosa* can modulate its
425 *oprD* expression to confer carbapenem AMR. Like *ampC*, our *oprD* results indicate that there may be
426 great clinical value in characterising *in vivo oprD* expression to rapidly identify *P. aeruginosa*
427 infections that are recalcitrant to carbapenem therapy.

428 **Concluding remarks**. Our results add further weight to growing concerns about the relevance of *in*
429 *vitro* AMR research, particularly *in vitro* gene expression analysis, in clinical practice (79, 80). Due to
430 poor correlation between *in vitro* AMR testing and treatment outcomes in CF, empirical antibiotic
431 selection remains the preferred option due to better patient responses (72). Our findings confirm
432 that alternative approaches must be explored that minimise the transcriptional biases introduced
433 during culture (81) to better reflect *in vivo P. aeruginosa* gene expression (79). We recommend that,
434 wherever possible, gene expression of clinical specimens (e.g. sputum) be tested alongside cultured
435 isolates (20). This information will greatly improve our understanding of the shortcomings of *in vitro*
436 AMR testing whilst aiding in clinical decision making, providing more targeted treatment strategies,
437 enhancing antimicrobial stewardship, and improving patient outcomes.

Acknowledgements

This work was supported by Advance Queensland (awards AQIRF0362018 and AQRF13016-17RD2), an Australian Government Research Training Program Scholarship, the Wishlist Sunshine Coast Health Foundation (award 2019-14), the IMPACT Philanthropy Application Program (IPAP2016/01112), UQ-QIMRB (Australian Infectious Disease Grant initiative), the National Health and Medical Research Council (award 455919), The Children's Health Foundation Queensland (50 0 07), and The Health Innovation, Investment and Research Office of Queensland Health. The funders had no role in study design, data acquisition, analysis, interpretation, writing or submission of the manuscript.

447 **Tables**

448 **Table 1. *Pseudomonas aeruginosa*-positive sputa, corresponding derived isolates, and disc diffusion profiles across 11 anti-pseudomonal antibiotics**

Disease	Sputum ID†	Derived isolate ID	Aminoglycosides		Penicillins		Cephalosporins		FQs	Polymyxins		Carbapenems		Treatment	AMR prediction from genomic data
			AMK	TOB	PIP	TZP	CAZ	FEP	CIP	CST	PMB	IPM	MEM#		
CF	SCHI0002 (Day 8)	SCHI0002.S.8	S	S	R	I	I	R	I	S	S	R	S	IV CAZ, MEM, TOB	GyrB S466F (CIPi); OprD W339Ter (MEMr, IPMr); FtsI R504C (MEMr, IPMr, CAZr; FEPr, TZPr, PIPr)
		SCHI0002.S.9	R	S	R	R	R	R	I	S	S	R	R	IV CAZ, MEM, TOB	NalD D187H (CIPi, FEPi, CAZi, MEMi, IPMi); PA3127 loss (PIPr)
	SCHI0002 (Day 329)	SCHI0002.S.12	R	R	R	R	R	R	I	S	S	S	S	IV CAZ, MEM, TOB	NalD D187H (CIPi, FEPi, CAZi, MEMi, IPMi); PA2326 loss (PIPr, FEPr); PA3127 loss (PIPr)
	SCHI0010 (Day 7)	SCHI0010.S.1	R	R	R	R	R	R	R	S	S	R	R	IV CAZ, TOB	FusA1 A555E (AMKr, TOBr); GyrA T83I (CIPr); PA2693 D17fs (PIPr, TZPr, MEMr, FEPr, CAZr); PA2531 A137fs (PIPr); PckA G418fs (PIPr); *aac(6')-IIa* (TOBr)
	SCHI0013 (Day 4)	SCHI0013.S.2	S	R	S	S	S	I	S	S	S	R	S	IV FOF, MEM	GyrB S466Y (CIPi), ParE A473V (CIPi), PA1942 loss (PIPr), MexE R229fs (CIPs); *ant(2'')-Ia* (TOBr)
		SCHI0013.S.12	R	S	R	S	S	R	I	S	S	R	I	IV FOF, MEM	GyrB S466Y (CIPi); ParE A473V (CIPi); MexE R229fs (CIPs)
	SCHI0018 (Day 8)	SCHI0018.S.11	S	R	R	I	R	I	S	S	S	S	---	IV CAZ, TZP, TOB	Not sequenced
	SCHI0030 (Day 0)	SCHI0030.S.1	S	S	S	S	S	I	S	S	S	S	S	Nil	None
	SCHI0030 (Day 6)	SCHI0030.S.2	R	R	R	R	R	R	I	S	S	R	R	IV ATM, TOB	PA1821 loss (PIPr, TZPr); MexF Y37Ter (CIPs); AmpD P42fs (CAZi, PIPi, TZPi, FEPi, IPMi, MEMi); FtsI R504C (MEMr, IPMr, CAZr, FEPr, TZPr, PIPr); GyrA D87H (CIPr)
	SCHI0030 (Day 13)	SCHI0030.S.3	R	I	R	R	R	R	R	S	S	R	R	IV ATM, TOB	AmpD P42fs (CAZi, PIPi, TZPi, FEPi, MEMi, IPMi); OprD G193fs (MEMr, IPMr); MexF

															Y37Ter (CIPs); FtsI R504C (MEMr, IPMr, CAZr, FEPr, TZPr, PIPr); GyrA D87H (CIPr)
	SCHI0030 (Day 50)*	SCHI0030.S.4	R	R	R	R	R	R	R	S	S	R	R	Nil	NfxB F126fs (CIPr, FEPr)
		SCHI0030.S.5	S	S	S	S	S	S	S	S	S	S	S	Nil	None
COPD	SCHI0038*	SCHI0038.S.2	I	R	S	S	S	S	S	S	S	S	S	Nil	Not sequenced
		SCHI0038.S.3	S	S	S	S	S	S	S	S	S	S	S	Nil	None
		SCHI0038.S.4	S	I	S	S	S	S	S	S	S	S	S	Nil	Not sequenced
	SCHI0039*	SCHI0039.S.1	S	S	S	S	S	S	S	S	S	S	S	Nil	PA0090 R532_E535delinsQ (TZPr, FEPr, PIPr)
	SCHI0050 (Day 3)	SCHI0050.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral CIP	ParC Q405R (precursor; causes CIPr in combination with a *gyrA* mutation)
	SCHI0065*	SCHI0065.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral AZM	None
	SCHI0070 (Day 2)*	SCHI0070.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral AMC	None
	SCHI0109	Not retrieved	---	---	---	---	---	---	---	---	---	---	---	Oral CIP and AZM; azathioprine	---
Control	---	PAO1	S	S	S	S	S	S	S	S	S	S	S	---	None

Abbreviations: AMK, amikacin; AMR, antimicrobial resistance; ATM, aztreonam; AZM, azithromycin; CAZ, ceftazidime; cDNA, complementary DNA; CF, cystic fibrosis; CIP, ciprofloxacin; CST, colistin; COPD, chronic obstructive pulmonary disease; FEP, cefepime; FOF, fosfomycin; FQ, fluoroquinolones; fs, frameshift; I or i, intermediate resistance; IPM, imipenem; MEM, meropenem; PMB, polymyxin B; PIP, piperacillin; R or r, antimicrobial resistant; S or s, antimicrobial sensitive; TZP, piperacillin/tazobactam; TOB, tobramycin; AZM, azithromycin; AMC, amoxicillin/clavulanic acid

[†]Days since commencing antibiotics

*Not receiving anti-pseudomonal antibiotics at time of sputum collection

#MEM antibiotic resistance profiles were determined using E-Tests

456 **Table 2. Primers and probes designed in this study**

Multiplex	Gene target	AMR target	Fluorophore	Oligo name	Oligo sequence (5'-3')	Optimised concentration (µM)
1	***mexY***	RND efflux pump	HEX	mexY-For	AAGAGGACCAGGGCGACTTC	0.20
				mexY-Rev	CTTCAGGGTGGCGAAGATCAT	0.20
				mexY-Probe	TGAAGCCGCCGACCGCA	0.20
	mexB	RND efflux pump	FAM	mexB-For	ACCGTGGTCCAGGTGATCG	0.15
				mexB-Rev	AGTTACTCTCCGAGGAGATGTAGCG	0.15
				mexB-Probe	CAGCAGATGAACGGGATCG	0.20
	ampC	β-lactamase	Texas Red	ampC-For	CTTCGACGGCATCAGCCT	0.45
				ampC-Rev	CCGATGCTCGGGTTGGA	0.45
				ampC-Probe	CAGATCCGCGACTACTACCGCCAGTG	0.20
	rpsL	Housekeeping gene	Cy5	rpsL-For	CGACAAGAGCGACGTGCC	0.25
				rpsL-Rev	TTACGCAGTGCCGAGTTCG	0.25
				rpsL-Probe	CATACGCCACGACGTTGCG	0.20
2	***mexC***	RND efflux pump	HEX	mexC-For	GTGCTGTTCGAGGCGCAG	0.20
				mexC-Rev	TCCTGCTGGCTGACCGC	0.20
				mexC-Probe	CTGGATCTTCACCAGCGGCT	0.25
	oprD	Porin	FAM	oprD-For	AAGTGGAGCGCCATTGCA	0.20
				oprD-Rev	TAGTAGTTGCGGAGCAGCAGGT	0.20
				oprD-Probe	CTGCTGTCTTCGATGAACC	0.20
	mexE	RND efflux pump	Texas Red	mexE-For	TACCTCGGCCTGAGCAGC	0.25
				mexE-Rev	GTTGACCTGGTTGTCGAGGAAG	0.25
				mexE-Probe	ACGGCAACCCGCACCTG	0.30

457 Abbreviations: AMR, antimicrobial resistant (allele); cDNA, complementary DNA; RND, resistance-

458 nodulation-division; SNP, single-nucleotide polymorphism; WT, wild-type (allele)

459 *Bolded nucleotides indicate the SNP; underlined nucleotides indicate deliberately incorporated

460 antepenultimate/penultimate mismatches to enhance allele specificity

461 **Figures**

462



463

464 **Figure 1.** *In vivo* expression of *Pseudomonas aeruginosa* antimicrobial resistance loci in six cystic
465 fibrosis (CF) and five chronic obstructive pulmonary disease (COPD) sputa. Gene expression for each
466 sample at each locus was first normalised against *rpsL* (ΔC_T); relative expression was then
467 determined by comparing ΔC_T values against COPD participant SCHI0070 (i.e. $\Delta\Delta C_T$), who was not
468 receiving anti-pseudomonal antibiotics at the time of sputum collection. For SCHI0030, in which
469 longitudinal sputa over antibiotic treatment were obtained, only the Day 0 sputum was used in this
470 analysis to ensure independence of all observations. *, adjusted p <0.05, **, adjusted p <0.01. Error
471 bars=95% confidence interval.

472



473 **Figure 2.** Differential expression (relative fold change) of *Pseudomonas aeruginosa* antimicrobial
474 resistance loci in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) sputa. Gene
475 expression for each locus was first normalised against *rpsL* (ΔC_T); relative expression was then
476 determined by comparing ΔC_T values against COPD participant SCHI0070 (i.e. $\Delta\Delta C_T$), who was not
477 receiving anti-pseudomonal antibiotics at the time of sputum collection. For participants receiving
478 anti-pseudomonal antibiotics, sputa are denoted by 'Day post-antibiotics' (D) (see Table 1 for
479 details). Error bars, standard deviation. †Participants receiving non-pseudomonal antibiotics at the
480 time of sputum collection.

481 **References**

482 1. Alanis AJ. 2005. Resistance to antibiotics: Are we in the post-antibiotic era? Archives of
483 Medical Research 36:697-705.
484 2. Zhen X, Lundborg CS, Sun X, Hu X, Dong H. 2019. Economic burden of antibiotic resistance in
485 ESKAPE organisms: a systematic review. Antimicrob Resist Infect Control 8:137.
486 3. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. 2019. Emerging strategies to
487 combat ESKAPE Pathogens in the era of antimicrobial resistance: A review. Front Microbiol
488 10:539-539.
489 4. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. 2018. How to manage *Pseudomonas*
490 *aeruginosa* infections. Drugs Context 7:1-18.
491 5. Botelho J, Grosso F, Peixe L. 2019. Antibiotic resistance in *Pseudomonas aeruginosa* -
492 Mechanisms, epidemiology and evolution. Drug Resist Updat 44:26-47.
493 6. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. 2011. *Pseudomonas aeruginosa*: All
494 roads lead to resistance. Trends Microbiol 19:419-26.
495 7. Shallcross LJ, Howard SJ, Fowler T, Davies SC. 2015. Tackling the threat of antimicrobial
496 resistance: From policy to sustainable action. Philos Trans R Soc Lond B Biol Sci 370:1-5.
497 8. O'Neill J. 2014. Antimicrobial resistance: Tackling a crisis for the health and wealth of
498 nations. Accessed 12 August 2021.
499 9. Patel A. 2021. Tackling antimicrobial resistance in the shadow of COVID-19. mBio 12:1-4.
500 10. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E, Hara
501 GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E,
502 Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown
503 ED, Cars O. 2013. Antibiotic resistance - the need for global solutions. Lancet Infect Dis
504 13:1057-1098.
505 11. Su M, Satola SW, Read TD. 2019. Genome-based prediction of bacterial antibiotic resistance.
506 J Clin Microbiol 57:1-15.
507 12. Rossen JWA, Friedrich AW, Moran-Gilad J. 2018. Practical issues in implementing whole-
508 genome-sequencing in routine diagnostic microbiology. Clin Microbiol Infect 24:355-360.
509 13. Madden DE, McCarthy KL, Bell SC, Olagoke O, Baird T, Neill J, Ramsay KA, Kidd TJ, Stewart
510 AG, Subedi S, Choong K, Fraser TA, Sarovich DS, Price EP. 2021. Rapid fluoroquinolone
511 resistance detection in *Pseudomonas aeruginosa* using mismatch amplification mutation
512 assay-based real-time PCR. *medRxiv*.
513 14. Richardot C, Plesiat P, Fournier D, Monlezun L, Broutin I, Llanes C. 2015. Carbapenem
514 resistance in cystic fibrosis strains of *Pseudomonas aeruginosa* as a result of amino acid
515 substitutions in porin OprD. Int J Antimicrob Agents 45:529-32.
516 15. Godfroid M, Dagan T, Merker M, Kohl TA, Diel R, Maurer FP, Niemann S, Kupczok A. 2020.
517 Insertion and deletion evolution reflects antibiotics selection pressure in a *Mycobacterium*
518 *tuberculosis* outbreak. PLoS Pathog 16:1-24.
519 16. Huang TW, Chen TL, Chen YT, Lauderdale TL, Liao TL, Lee YT, Chen CP, Liu YM, Lin AC, Chang
520 YH, Wu KM, Kirby R, Lai JF, Tan MC, Siu LK, Chang CM, Fung CP, Tsai SF. 2013. Copy number
521 change of the NDM-1 sequence in a multidrug-resistant *Klebsiella pneumoniae* clinical
522 isolate. PLoS One 8:1-12.
523 17. Chalhoub H, Sáenz Y, Rodriguez-Villalobos H, Denis O, Kahl BC, Tulkens PM, Van Bambeke F.
524 2016. High-level resistance to meropenem in clinical isolates of *Pseudomonas aeruginosa* in
525 the absence of carbapenemases: role of active efflux and porin alterations. Int J Antimicrob
526 Agents 48:740-743.
527 18. Stewart AG, Price EP, Schabacker K, Birikmen M, Harris PNA, Choong K, Subedi S, Sarovich
528 DS. 2021. Molecular epidemiology of third-generation cephalosporin-resistant
529 *Enterobacteriaceae* in Southeast Queensland, Australia. Antimicrob Agents Chemother 65:1-
530 13.

531 19. Chantratita N, Rholl DA, Sim B, Wuthiekanun V, Limmathurotsakul D, Amornchai P,
532 Thanwisai A, Chua HH, Ooi WF, Holden MT, Day NP, Tan P, Schweizer HP, Peacock SJ. 2011.
533 Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in
534 *Burkholderia pseudomallei*. Proc Natl Acad Sci U S A 108:17165-70.
535 20. Martin LW, Robson CL, Watts AM, Gray AR, Wainwright CE, Bell SC, Ramsay KA, Kidd TJ, Reid
536 DW, Brockway B, Lamont IL. 2018. Expression of *Pseudomonas aeruginosa* antibiotic
537 resistance genes varies greatly during infections in cystic fibrosis patients. Antimicrob Agents
538 Chemother 62:1-11.
539 21. Wheatley R, Diaz Caballero J, Kapel N, de Winter FHR, Jangir P, Quinn A, del Barrio-Tofiño E,
540 López-Causapé C, Hedge J, Torrens G, Van der Schalk T, Xavier BB, Fernández-Cuenca F,
541 Arenzana A, Recanatini C, Timbermont L, Sifakis F, Ruzin A, Ali O, Lammens C, Goossens H,
542 Kluytmans J, Kumar-Singh S, Oliver A, Malhotra-Kumar S, MacLean C. 2021. Rapid evolution
543 and host immunity drive the rise and fall of carbapenem resistance during an acute
544 *Pseudomonas aeruginosa* infection. Nat Commun 12:1-12.
545 22. Lee JY, Ko KS. 2012. OprD mutations and inactivation, expression of efflux pumps and AmpC,
546 and metallo-beta-lactamases in carbapenem-resistant *Pseudomonas aeruginosa* isolates
547 from South Korea. Int J Antimicrob Agents 40:168-72.
548 23. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C,
549 Pena C, Martinez-Martinez L, Oliver A. 2011. Overexpression of *AmpC* and efflux pumps in
550 *Pseudomonas aeruginosa* isolates from bloodstream infections: prevalence and impact on
551 resistance in a Spanish multicenter study. Antimicrob Agents Chemother 55:1906-11.
552 24. Webb JR, Price EP, Somprasong N, Schweizer HP, Baird RW, Currie BJ, Sarovich DS. 2018.
553 Development and validation of a triplex quantitative real-time PCR assay to detect efflux
554 pump-mediated antibiotic resistance in *Burkholderia pseudomallei*. Future Microbiol
555 12:1403-1418.
556 25. Poole K. 2011. *Pseudomonas aeruginosa:* Resistance to the max. Front Microbiol 2:1-13.
557 26. Juan C, Moya B, Perez JL, Oliver A. 2006. Stepwise upregulation of the *Pseudomonas*
558 *aeruginosa* chromosomal cephalosporinase conferring high-level beta-lactam resistance
559 involves three AmpD homologues. Antimicrob Agents Chemother 50:1780-7.
560 27. Shu JC, Kuo AJ, Su LH, Liu TP, Lee MH, Su IN, Wu TL. 2017. Development of carbapenem
561 resistance in *Pseudomonas aeruginosa* is associated with *OprD* polymorphisms, particularly
562 the amino acid substitution at codon 170. J Antimicrob Chemother 72:2489-2495.
563 28. Sherrard LJ, Wee BA, Duplancic C, Ramsay KA, Dave KA, Ballard E, Wainwright CE, Grimwood
564 K, Sidjabat HE, Whiley DM, Beatson SA, Kidd TJ, Bell SC. 2021. Emergence and impact of *oprD*
565 mutations in *Pseudomonas aeruginosa* strains in cystic fibrosis. J Cyst Fibros 21:1-9.
566 29. Lee JK, Lee YS, Park YK, Kim BS. 2005. Alterations in the GyrA and GyrB subunits of
567 topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-
568 resistant clinical isolates of *Pseudomonas aeruginosa*. Int J Antimicrob Agents 25:290-5.
569 30. Poole K, Tetro K, Zhao Q, Neshat S, Heinrichs DE, Bianco N. 1996. Expression of the multidrug
570 resistance operon mexA-mexB-oprM in *Pseudomonas aeruginosa*: mexR encodes a regulator
571 of operon expression. Antimicrob Agents Chemother 40:2021-8.
572 31. Chen W, Wang D, Zhou W, Sang H, Liu X, Ge Z, Zhang J, Lan L, Yang CG, Chen H. 2016.
573 Novobiocin binding to NalD induces the expression of the MexAB-OprM pump in
574 *Pseudomonas aeruginosa*. Mol Microbiol 100:749-58.
575 32. Köhler T, Epp SF, Curty LK, Pechère JC. 1999. Characterization of MexT, the regulator of the
576 MexE-MexF-OprN multidrug efflux system of *Pseudomonas aeruginosa*. J Bacteriol
577 181:6300-5.
578 33. Morita Y, Tomida J, Kawamura Y. 2012. MexXY multidrug efflux system of *Pseudomonas*
579 *aeruginosa*. Front Microbiol 3:1-13.
580 34. Aghazadeh M, Hojabri Z, Mahdian R, Nahaei MR, Rahmati M, Hojabri T, Pirzadeh T, Pajand O.
581 2014. Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and

582 OprD porin in non-metallo-beta-lactamase producing *Pseudomonas aeruginosa* isolated
583 from cystic fibrosis and burn patients. Infect Genet Evol 24:187-92.
584 35. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ,
585 Nishino T. 1996. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type
586 multidrug-resistant strains of *Pseudomonas aeruginosa*. Mol Microbiol 21:713-24.
587 36. Fraud S, Campigotto AJ, Chen Z, Poole K. 2008. MexCD-OprJ multidrug efflux system of
588 *Pseudomonas aeruginosa:* Involvement in chlorhexidine resistance and induction by
589 membrane-damaging agents dependent upon the AlgU stress response sigma factor.
590 Antimicrob Agents Chemother 52:4478-4482.
591 37. Gotoh N, Tsujimoto H, Tsuda M, Okamoto K, Nomura A, Wada T, Nakahashi M, Nishino T.
592 1998. Characterization of the MexC-MexD-OprJ Multidrug Efflux System in mexA-mexB-
593 oprM Mutants of *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 42:1938-1943.
594 38. Oh H, Stenhoff J, Jalal S, Wretlind B. 2003. Role of efflux pumps and mutations in genes for
595 topoisomerases II and IV in fluoroquinolone-resistant *Pseudomonas aeruginosa* strains.
596 Microb Drug Resist 9:323-8.
597 39. Islam S, Jalal S, Wretlind B. 2004. Expression of the MexXY efflux pump in amikacin-resistant
598 isolates of *Pseudomonas aeruginosa*. Clin Microbiol Infect 10:877-83.
599 40. Webb KA, Olagoke O, Baird T, Neill J, Pham A, Wells TJ, Ramsay KA, Bell SC, Sarovich DS,
600 Price EP. 2021. Genomic diversity and antimicrobial resistance of *Prevotella* spp. isolated
601 from chronic lung disease airways. Microb Genom 8:000754.
602 41. Nadkarni MA, Martin FE, Jacques NA, Hunter N. 2002. Determination of bacterial load by
603 real-time PCR using a broad-range (universal) probe and primers set. Microbiology (Reading)
604 148:257-266.
605 42. De Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P. 1992. A one-step microbial DNA
606 extraction method using "Chelex 100" suitable for gene amplification. Res Microbiol
607 143:785-90.
608 43. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP. 2009.
609 Identification of *Pseudomonas aeruginosa* by a duplex real-time polymerase chain reaction
610 assay targeting the *ecfX* and the *gyrB* genes. Diagn Microbiol Infect Dis 63:127-131.
611 44. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, Benito N, Grau S. 2019.
612 Epidemiology and treatment of multidrug-resistant and extensively drug-resistant
613 *Pseudomonas aeruginosa* infections. Clin Microbiol Rev 32:1-52.
614 45. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. 2000. Substrate
615 specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in *Pseudomonas*
616 *aeruginosa*. Antimicrob Agents Chemother 44:3322-7.
617 46. Buffet-Bataillon S, Tattevin P, Maillard J-Y, Bonnaure-Mallet M, Jolivet-Gougeon A. 2016.
618 Efflux pump induction by quaternary ammonium compounds and fluoroquinolone resistance
619 in bacteria. Future Microbiol 11:81-92.
620 47. Fetar H, Gilmour C, Klinoski R, Daigle DM, Dean CR, Poole K. 2011. mexEF-oprN multidrug
621 efflux operon of *Pseudomonas aeruginosa:* Regulation by the MexT activator in response to
622 nitrosative stress and chloramphenicol. Antimicrob Agents Chemother 55:508-514.
623 48. Dunne WM, Jr., Hardin DJ. 2005. Use of several inducer and substrate antibiotic
624 combinations in a disk approximation assay format to screen for AmpC induction in patient
625 isolates of *Pseudomonas aeruginosa*, *Enterobacter* spp., *Citrobacter* spp., and *Serratia* spp. J
626 of Clin Microbiol 43:5945-5949.
627 49. Oliver A, Baquero F, Blázquez J. 2002. The mismatch repair system (mutS, mutL and uvrD
628 genes) in *Pseudomonas aeruginosa*: molecular characterization of naturally occurring
629 mutants. Mol Microbiol 43:1641-50.
630 50. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras J-B, Barbu EM, Shortridge D, Blanc
631 B, Hannum G, Zambardi G, Miller K, Enright MC, Mugnier N, Brami D, Schicklin S, Felderman
632 M, Schwartz AS, Richardson TH, Peterson TC, Hubby B, Cady KC. 2015. Phylogenetic

633 distribution of CRISPR-Cas systems in antibiotic-resistant *Pseudomonas aeruginosa*. mBio
634 6:1-13.
635 51. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MÁ, Zamorano L,
636 Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Plesiat P, Oliver A. 2016.
637 Deciphering the resistome of the widespread *Pseudomonas aeruginosa* sequence type 175
638 international high-risk clone through whole-genome sequencing. Antimicrob Agents
639 Chemother 60:7415-7423.
640 52. Kos VN, Déraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H.
641 2015. The resistome of *Pseudomonas aeruginosa* in relationship to phenotypic susceptibility.
642 Antimicrob Agents Chemother 59:427-436.
643 53. Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM,
644 Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E,
645 Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C,
646 Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A. 2017.
647 Genomics and susceptibility profiles of extensively drug-resistant *Pseudomonas aeruginosa*
648 isolates from Spain. Antimicrob Agents Chemother 61:1-13.
649 54. Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson SA,
650 Bell SC. 2017. Within-host whole genome analysis of an antibiotic resistant *Pseudomonas*
651 *aeruginosa* strain sub-type in cystic fibrosis. PLoS ONE 12:1-15.
652 55. Fraser TA, Bell MG, Harris PNA, Bell SC, Bergh H, Nguyen T-K, Kidd TJ, Nimmo GR, Sarovich
653 DS, Price EP. 2019. Quantitative real-time PCR assay for the rapid identification of the
654 intrinsically multidrug-resistant bacterial pathogen *Stenotrophomonas maltophilia*. Microb
655 Genom 5:2-11.
656 56. Price EP, Dale JL, Cook JM, Sarovich DS, Seymour ML, Ginther JL, Kaufman EL, Beckstrom-
657 Sternberg SM, Mayo M, Kaestli M, Glass MB, Gee JE, Wuthiekanun V, Warner JM, Baker A,
658 Foster JT, Tan P, Tuanyok A, Limmathurotsakul D, Peacock SJ, Currie BJ, Wagner DM, Keim P,
659 Pearson T. 2012. Development and validation of *Burkholderia pseudomallei*-specific real-
660 time PCR assays for clinical, environmental or forensic detection applications. PLoS One 7:1-
661 9.
662 57. Araujo P. 2009. Key aspects of analytical method validation and linearity evaluation. J
663 Chromatogr B Analyt Technol Biomed Life Sci 877:2224-34.
664 58. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time
665 quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-8.
666 59. Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS. 2021. Taking the next-gen
667 step: Comprehensive antimicrobial resistance detection from *Burkholderia pseudomallei*.
668 EBioMedicine 63:103152.
669 60. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A. 2005. Molecular mechanisms of β-
670 lactam resistance mediated by AmpC hyperproduction in *Pseudomonas aeruginosa* clinical
671 strains. Antimicrob Agents Chemother 49:4733-8.
672 61. Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N.
673 2010. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in *Pseudomonas*
674 *aeruginosa* isolates from cystic fibrosis patients. Antimicrob Agents Chemother 54:2219-
675 2224.
676 62. Purssell A, Poole K. 2013. Functional characterization of the NfxB repressor of the *mexCD-*
677 *oprJ* multidrug efflux operon of *Pseudomonas aeruginosa*. Microbiology (Reading) 159:2058-
678 2073.
679 63. Livermore DM. 1995. Beta-Lactamases in laboratory and clinical resistance. Clin Microbiol
680 Rev 8:557-84.
681 64. Rehman A, Jeukens J, Levesque RC, Lamont IL. 2021. Gene-gene interactions dictate
682 ciprofloxacin resistance in *Pseudomonas aeruginosa* and facilitate prediction of resistance
683 phenotype from genome sequence data. Antimicrob Agents Chemother 65:1-15.

684 65. Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis
685 DE, Guttman DS, Hwang DM. 2019. Penicillin-binding protein 3 is a common adaptive target
686 among *Pseudomonas aeruginosa* isolates from adult cystic fibrosis patients treated with β-
687 lactams. Int J Antimicrob Agents 53:620-628.
688 66. Bolard A, Plésiat P, Jeannot K. 2018. Mutations in gene fusA1 as a novel mechanism of
689 aminoglycoside resistance in clinical strains of *Pseudomonas aeruginosa*. Antimicrob Agents
690 Chemother 62:1-10.
691 67. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC. 1997.
692 Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of
693 *Pseudomonas aeruginosa*. Mol Microbiol 23:345-54.
694 68. Zamorano L, Moya B, Juan C, Oliver A. 2010. Differential beta-lactam resistance response
695 driven by *ampD* or *dacB* (PBP4) inactivation in genetically diverse *Pseudomonas aeruginosa*
696 strains. J Antimicrob Chemother 65:1540-2.
697 69. Winstanley C, O'Brien S, Brockhurst MA. 2016. *Pseudomonas aeruginosa* evolutionary
698 adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol
699 24:327-337.
700 70. Valderrey AD, Pozuelo MJ, Jiménez PA, Maciá MD, Oliver A, Rotger R. 2010. Chronic
701 colonization by *Pseudomonas aeruginosa* of patients with obstructive lung diseases: cystic
702 fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagn Microbiol Infect
703 Dis 68:20-7.
704 71. Lee M, Hesek D, Blázquez B, Lastochkin E, Boggess B, Fisher JF, Mobashery S. 2015. Catalytic
705 spectrum of the penicillin-binding protein 4 of *Pseudomonas aeruginosa*, a nexus for the
706 induction of β-lactam antibiotic resistance. J Am Chem Soc 137:190-200.
707 72. Van den Bossche S, De Broe E, Coenye T, Van Braeckel E, Crabbé A. 2021. The cystic fibrosis
708 lung microenvironment alters antibiotic activity: Causes and effects. Eur Respir Rev 30:1-16.
709 73. Vettoretti L, Plesiat P, Muller C, El Garch F, Phan G, Attree I, Ducruix A, Llanes C. 2009. Efflux
710 unbalance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. Antimicrob
711 Agents Chemother 53:1987-97.
712 74. Goodman AL, Kulasekara B, Rietsch A, Boyd D, Smith RS, Lory S. 2004. A signaling network
713 reciprocally regulates genes associated with acute infection and chronic persistence in
714 *Pseudomonas aeruginosa*. Dev Cell 7:745-54.
715 75. Werner E, Roe F, Bugnicourt A, Franklin MJ, Heydorn A, Molin S, Pitts B, Stewart PS. 2004.
716 Stratified growth in *Pseudomonas aeruginosa* biofilms. Appl Environ Microbiol 70:6188-96.
717 76. Murphy TF. 2008. The many faces of *Pseudomonas aeruginosa* in chronic obstructive
718 pulmonary disease. Clin Infect Dis 47:1534-1536.
719 77. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, *ampC*, and *oprD*
720 expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates.
721 Antimicrob Agents Chemother 50:1633-1641.
722 78. Pai H, Kim J, Kim J, Lee JH, Choe KW, Gotoh N. 2001. Carbapenem resistance mechanisms in
723 *Pseudomonas aeruginosa* clinical isolates. Antimicrob Agents Chemother 45:480-4.
724 79. Fung C, Naughton S, Turnbull L, Tingpej P, Rose B, Arthur J, Hu H, Harmer C, Harbour C,
725 Hassett DJ, Whitchurch CB, Manos J. 2010. Gene expression of *Pseudomonas aeruginosa* in a
726 mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum. J Med
727 Microbiol 59:1089-1100.
728 80. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, MacLeod C, Aaron
729 SD, Harbour C. 2005. Antibiotic susceptibilities of *Pseudomonas aeruginosa* isolates derived
730 from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J of Clin
731 Microbiol 43:5085-5090.
732 81. Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C. 2012. Use of artificial
733 sputum medium to test antibiotic efficacy against *Pseudomonas aeruginos*a in conditions
734 more relevant to the cystic fibrosis lung. J Vis Exp 64:1-7.